Pediatrix Medical Group, Inc. cash flow to debt ratio of 41.06% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Pediatrix Medical Group, Inc.'s free cash flow has increased 36.89% from $184.55M last year to $252.63M, signaling increasing performance

Pediatrix Medical Group, Inc.'s debt to equity ratio is 0.70, which means that the company's assets are unhealthy financed, signaling financial risk.

Pediatrix Medical Group, Inc.'s debt has decreased relative to shareholder equity from 0.87 last year to 0.70 today, signaling strengthened financials

Pediatrix Medical Group, Inc. has a net debt to EBITDA ratio of 0.59x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Pediatrix Medical Group, Inc.'s interest coverage ratio of 8.01 indicates that earnings with good margin can cover interest payments on company debt

Pediatrix Medical Group, Inc.'s profit margin has increased (-282.08%) in the last year from -4.92% to 8.96%, signaling increasing performance

Pediatrix Medical Group, Inc.'s short-term assets of $763.51M exceed its short-term liabilities of $458.91M

Pediatrix Medical Group, Inc.'s return on assets of 8.21% is higher than the 5.00% threshold, indicating efficient asset utilization

Pediatrix Medical Group, Inc.'s return on equity of 19.89%, is higher than 15.00%, indicating good performance

Pediatrix Medical Group, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Pediatrix Medical Group, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings

Pediatrix Medical Group, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Pediatrix Medical Group, Inc. has a free cash flow yield of 11.80%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Pediatrix Medical Group, Inc.'s yearly earnings has increased -266.94% since last year from $-99.07M to $165.39M, signaling increasing performance

Pediatrix Medical Group, Inc.'s yearly revenue has decreased 4.92% since last year from $2.01B to $1.91B, signaling decreasing performance

ROIC 9.57% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Pediatrix Medical Group, Inc.'s 3-year revenue CAGR of -0.99% is negative, indicating declining revenue over the past 3 years

Pediatrix Medical Group, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Pediatrix Medical Group, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity

Pediatrix Medical Group, Inc. is undervalued relative to its fair value price of 45.37 based on Discounted Cash Flow model

Pediatrix Medical Group, Inc. has an earnings yield of 8.44%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Pediatrix Medical Group, Inc. is overvalued relative to its fair value price of 19.68 based on EBITDA multiple model

Pediatrix Medical Group, Inc. has an EV/EBITDA ratio of 8.40x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Pediatrix Medical Group, Inc. is overvalued relative to its fair value price of 20.19 based on Earnings Fair Value model

Pediatrix Medical Group, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Pediatrix Medical Group, Inc. has a price-to-book ratio of 2.35x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Pediatrix Medical Group, Inc. has a price-to-sales ratio of 1.06x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue